Meeting
2014 ASCO Annual Meeting
Hepatic oligometastases treated with stereotactic body radiation therapy: Updated 10-year analysis of the Indiana University experience.
Authors
Ben Goodman
Indiana University, Indianapolis, IN
Ben Goodman , Higinia Rosa Cardenes , Mary A. Maluccio , Paul R. Helft
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3583)
DOI
10.1200/jco.2014.32.15_suppl.3583
Abstract #
3583
Poster Bd #
46
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.
First Author: Luca Faustino Valle
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II trial of combination of PD-1 immune checkpoint inhibition with all-lesion stereotactic radiation (SBRT) in oligometastatic renal cell carcinoma (omRCC).
First Author: Jing Liu
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz
Poster
2022 ASCO Genitourinary Cancers Symposium
ARTO trial-(NCT03449719): Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing I line treatment with abiraterone acetate.
First Author: Giulio Francolini